Inhibition of HuR/ELAVL-1 attenuates fibrotic progression in Mdx mice with dilated cardiomyopathy
Cellular and Molecular Life Sciences · 2025
DOI: 10.1007/s00018-025-05979-0 ↗At a glance
Journal article in Cellular and Molecular Life Sciences, 2025. Written by Andrea Farini and 12 co-authors. Institution: Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Major MEDLINE topics: ELAV-Like Protein 1, Cardiomyopathy, Dilated, Muscular Dystrophy, Duchenne. 106 references. The full text is freely available (open access, CC BY 4.0). Funded by: Università degli Studi di Milano.
Abstract (original language)
Duchenne muscular dystrophy (DMD) arises from dystrophin deficiency, a crucial component of the dystrophin-glycoprotein complex (DGC) essential for maintaining cellular structural integrity by linking intracellular actin filaments to the basal lamina. Dysfunctions within this complex, coupled with increased inflammatory immune cell infiltration, contribute to the onset of dilated cardiomyopathy (DCM). This cardiac condition, characterized by necrosis and fibrosis, significantly impairs left ventricular function. Despite various treatment approaches, reliable effects on these pathogenic mechanisms remain elusive. RNA-binding proteins play pivotal roles in modulating pathways often dysregulated in cardiac pathology. Notably, HuR, which is upregulated in fibrotic cardiac regions and modulates innate immune system activation, emerges as a promising target. We investigated HuR expression in cardiac tissues of mdx murine model of DMD and assessed the impact of its inhibition with regards to DCM progression. Our findings reveal that HuR is indeed upregulated in mdx mice, and its inhibition leads to attenuation of cardiac fibrosis and improvement in heart function. These preclinical results underscore the potential of targeting HuR for therapeutic intervention to mitigate DCM-associated pathological changes, warranting further exploration for the development of effective treatments.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Stem Cell Laboratory, Department of Pathophysiology and Transplantation, Dino Ferrari Centre, Università degli Studi di Milano, Neurology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Via Fra…
- Molecular Biotechnology Center "Guido Tarone", Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, Torino, 10126, Italy.
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, and Maternal and Children's Sciences (DINOGMI), University of Genoa, Genoa, Italy.
- Eli and Edythe Broad Center for Regenerative Medicine, University of Southern California, Los Angeles, USA.
- Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. yvan.torrente@unimi.it.
Funding
- Università degli Studi di Milano
Cite
APA
Farini, A., Molinaro, M., Mostosi, D., Camera, M., Russo, M., Leonetti, E., Meregalli, M., Prandi, L., Liaci, C., Ghigo, A., Hirsch, E., Merlo, G., & Torrente, Y. (2025). Inhibition of HuR/ELAVL-1 attenuates fibrotic progression in Mdx mice with dilated cardiomyopathy. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-025-05979-0
Vancouver
Farini A, Molinaro M, Mostosi D, Camera M, Russo M, Leonetti E, et al. Inhibition of HuR/ELAVL-1 attenuates fibrotic progression in Mdx mice with dilated cardiomyopathy. Cellular and Molecular Life Sciences. 2025. doi:10.1007/s00018-025-05979-0
BibTeX
@article{Farini2025,
author = {Farini, Andrea and Molinaro, Monica and Mostosi, Debora and Camera, Mattia and Russo, Michele and Leonetti, Emma and Meregalli, Mirella and Prandi, Lucia and Liaci, Carla and Ghigo, Alessandra and Hirsch, Emilio and Merlo, Giorgio and Torrente, Yvan},
title = {Inhibition of HuR/ELAVL-1 attenuates fibrotic progression in Mdx mice with dilated cardiomyopathy},
journal = {Cellular and Molecular Life Sciences},
year = {2025},
doi = {10.1007/s00018-025-05979-0}
}
EUVIMED